Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Bladder Cancer, Malignant Melanoma, Non-Small-Cell Lung Cancer, Renal Cell Carcinoma (TBC) | Access and Reimbursement | US | 2016
Immune checkpoint inhibitors have entered multiple oncology indications but the high costs associated with these agents present significant challenges for payers. The potential for label expansions…